REC Ref.	IRAS No.	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Maximum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Target Date To Recruit Patients Agreed?	Date Agreed to recruit target number of patients	Total Number Of Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Total Number Of Study Participants Recruited	Reason For Closure Of Trial
17/LO/0401	217921	An Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Combination with Sofosbuvir and Ribavirin in Chronic Hepatitis C (HCV) Infected Subjects Who Have Experienced Virologic Failure in AbbVie HCV Clinical Studies.	Number Agreed	1	1	Date Agreed	09/02/2018	1	23/06/2017	1	Recruitment Finished
17/YH/0076	208944	CALM-DIEM_UK ? CONTROLLING AND LOWERING BLOOD PRESSURE WITH THE MOBIUSHD?? DEFINING EFFICACY MARKERS	Not Available / Not Agreed			Not Available / Not Agreed			23/11/2017	0	Withdrawn By Sponsor
16/SW/0201	205118	Open-label Phase-4 study to ezamine the change of vision-related quality of life in subjects with diabetic macular edema (DME) during treatment with intravitreal injections of 2mg aflibercept according to EU label for the first year of treatment	Not Available / Not Agreed			Not Available / Not Agreed			13/12/2017	0	Withdrawn By Sponsor
17/EM/0338	229242	A phase 3, multi-center, open-label, randomized study of oral ABL001 versus bosutinib in patients with Chronic Myelogenous Leukemia in chronic phase (CML-CP), previously treated with 2 or more tyrosine kinase inhibitors	Number Agreed	1	1	Date Agreed	22/11/2018	0	26/10/2017	0	Withdrawn By Sponsor
17/LO/1091	229631	A Phase 3 Clinical Study to Evaluate the Efficacy and Safety of the Combination Regimen of MK-3682B (Grazoprevir/Ruzasvir/Uprifosbuvir) in Participants with Chronic Hepatitis C Virus Genotype 3 Infection	Number Agreed	4	4	Not Available / Not Agreed			18/10/2017	0	Withdrawn By Sponsor
17/EE/0100	215559	A prospective, consecutively enrolling, non-randomized multi centre post-market registry to evaluate the low profile (14F) Ovation? Abdominal Stent Graft Platform when used in the endovascular treatment of female patients with abdominal aortic aneurysm	Number Agreed	5	5	Date Agreed	30/04/2018	0	07/12/2017	0	Withdrawn By Sponsor
16/EE/0463	214371	An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced br	Number Agreed	1	1	Date Agreed	31/10/2017	1	07/11/2017	1	Recruitment Finished
17/LO/0401	217921	An Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Combination with Sofosbuvir and Ribavirin in Chronic Hepatitis C (HCV) Infected Subjects Who Have Experienced Virologic Failure in AbbVie HCV Clinical Studies.	Number Agreed	1	1	Date Agreed	09/02/2018	1	23/06/2017	1	Recruitment Finished
17/LO/0418	220385	A Phase II Multi Centre Study of BGB324 in Combination with Pembrolizumab in Patients with Previously Treated Advanced Adenocarcinoma of the Lung	Number Agreed	3	3	Not Available / Not Agreed			02/11/2017	0	Withdrawn By Sponsor
16/NE/0415	217915	A Phase 2a, Open-Label Study to Evaluate the Safety, Pharmacokinetics and Efficacy of the Combination of AL-335 and Odalasvir (ODV), with or without Simeprevir (SMV), in Treatment-Na?ve Subjects with Genotype 1, 2 or 3 Chronic Hepatitis C infection with or	Number Agreed	5	5	Date Agreed	30/06/2018	0	18/10/2017	0	Withdrawn By Sponsor
	213250	24-month prospective, multicentre, non-interventional study to evaluate the effectiveness of Elocta compared to conventional factor products in the prophylactic treatment of patients with haemophilia A	Number Agreed	0	0	Not Available / Not Agreed			09/03/2017	0	Withdrawn By Sponsor
16/WS/0005	193858	A PHASE 3, LONG-TERM ACTIVE TREATMENT EXTENSION STUDY OF MONGERSEN (GED-0301) IN SUBJECTS WITH CROHN?S DISEASE	Range Agreed	1	2	Date Agreed	31/10/2017	0	10/11/2017	0	Withdrawn By Sponsor

16/LO/2038	208640	A Double-blind, Randomized, Parallel-group, Placebo-controlled Study of MLE4901 for the Treatment of Polycystic Ovary Syndrome (PCOS)	Number Agreed	5	5	Date Agreed	31/05/2017	0	22/03/2017	0	Withdrawn By Sponsor
16/LO/1984	215378	A Phase 2, Open-Label Clinical Trial to Study the Efficacy and Safety of 12 weeks of the Combination Regimen of MK-3682 + MK-8408 in Subjects with Chronic Hepatitis C Virus (HCV) Genotype 1, 2, 3, 4, 5 or 6 Infection	Number Agreed	4	4	Date Agreed	10/03/2017	5	29/03/2017	5	Recruitment Finished
16/EE/0526	217214	A controlled, randomized, multi-centre, double blind, phase II study to evaluate efficacy and safety of topical PeproStatTM and absorbable haemostatic gelatin sponge in intraoperative surgical haemostasis	Not Available / Not Agreed			Not Available / Not Agreed			07/07/2017	0	Withdrawn By Sponsor
17/LO/0100	200545	A Multicenter, Randomized, Open-label Clinical Study of S-649266 or Best Available Therapy for the Treatment of Severe Infections Caused by Carbapenem-resistant Gram-negative Pathogens	Number Agreed	3	3	Date Agreed	31/05/2018	0	22/09/2017	0	Withdrawn By Sponsor
16/SC/0441	209391	A Phase 1, First-in-Humans, randomized, double-blind (within dose level),placebo-controlled trial to evaluate the safety and immunogenicity of two intranasal doses of SynGEM?, an intranasal Respiratory Syncytial Virus (RSV) subunit candidate vaccine based	Number Agreed	48	48	Date Agreed	25/01/2017	48	27/01/2017	48	Recruitment Finished
16/WM/0271	200160	Prospective, Single-Arm, Multi-Centre Study to Evaluate the Contour Neurovascular System?	Number Agreed	10	10	Date Agreed	07/07/2021	4	27/01/2017	4	Withdrawn By Sponsor
15/NW/0385	180668	A Four-Part Phase-1 Study Investigating the Tolerability, Safety and Pharmacokinetics (PK) of MBS2320 following Ascending Single and Multiple Oral Doses in Healthy Subjects and Multiple Oral Doses in Subjects with Rheumatoid Arthritis (RA) Also Treated wit	Range Agreed	2	7	Date Agreed	21/10/2017	4	23/03/2017	4	Recruitment Finished
16/NW/0305	201856	A PHASE III, MULTICENTRE, RANDOMISED, DOUBLE BLIND, PARALLEL GROUP, PLACEBO CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF ONE OR MORE INTRADETRUSOR TREATMENTS OF 600 OR 800 UNITS OF DYSPORT? FOR THE TREATMENT OF URINARY INCONTINENCE IN SUBJECTS WIT	Number Agreed	20	20	Not Available / Not Agreed			07/03/2017	0	Withdrawn By Sponsor
16/LO/0586	200579	An Open Label Study to Evaluate the Efficacy and Safety of Ocrelizumab in Patients with Relasping Remitting Multiple Sclerosis who have had a Suboptimal Response to an Adequate Course of Disease- Modifying Treatment	Number Agreed	3	3	Date Agreed	31/07/2017	3	03/03/2017	3	Recruitment Finished
16/LO/0016	195795	A Phase 3, Randomized, Open-Label Study to Evaluate the Safety and Efficacy of Switching from Regimens consisting of Boosted Atazanavir or Darunavir plus either Emtricitabine/Tenofovir or Abacavir/Lamivudine to GS-9883/Emtricitabine/Tenofovir Alafenamide i	Number Agreed	10	10	Date Agreed	31/05/2016	2	07/03/2017	2	Withdrawn By Sponsor
16/SC/0422	209437	A PHASE 2A STUDY OF TRC105 (WITH OPTION TO ADD STANDARD DOSE BEVACIZUMAB) IN PATIENTS WITH REFRACTORY GESTATIONAL TROPHOBLASTIC NEOPLASIA (GTN)	Number Agreed	02/01/1900	02/01/1900	Date Agreed	01/05/2018	0	42947	0	Withdrawn By Sponsor
15/SC/0306	176881	A phase 3,Randomized,Double-Blind,Placebo-Controlled Study of Ramacirumab plus Doxetacel vs Placebo plus Doxetacel in Patients with Locally Advanced or Unresectable or Metasthatic Urothelial Carcinoma Who Progressed or After Platinum-Based Therapy	Number Agreed	03/01/1900	03/01/1900	Date Agreed	01/02/2017	3	42814	3	Recruitment Finished
16/EM/0180	199125	A Multicentre Dose-Finding, Randomised, Double-Blind, Placebo-Controlled Study to Select the Daily Oral Dose of Estetrol (E4) for the Treatment of Vasomotor Symptoms in Post-Menopausal Women	Number Agreed	08/01/1900	08/01/1900	Date Agreed	21/09/2017	3	42976	3	Withdrawn By Sponsor
16/EM/0078	199717	Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Multicenter, Exploratory Phase IIa Study to Assess Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Properties of GLPG1690 Administered for 12 Weeks in Subjects with Idiopathic Pulmonar	Number Agreed	01/01/1900	01/01/1900	Date Agreed	17/11/2016	0	42766	0	Recruitment Finished

16/EE/0195	200168	A randomized, double-blind phase 3 study of vadastuximab talirine (SGN-CD33A) versus placebo in combination with azacitidine or decitabine in the treatment of older patients with newly diagnosed acute myeloid leukemia (AML)	Number Agreed	03/01/1900	03/01/1900	Not Available / Not Agreed			42906	1	Withdrawn By Sponsor
15/NW/0671	184963	A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Enzalutamide in Subjects with Advanced Hepatocellular Carcinoma	Number Agreed	02/01/1900	02/01/1900	Date Agreed	01/12/2016	3	42850	3	Recruitment Finished
16/SC/0161	186322	A Phase III, Open-Label, Randomized Study Of Atezolizumab (Mpdl3280a, Anti-Pd-L1?Antibody) In Combination With Carboplatin?Or Cisplatin?+?Pemetrexed Compared With Carboplatin Or Cisplatin?+?Pemetrexed In Patients Who Are Chemotherapy-Naive And Have Stage?I	Number Agreed	06/01/1900	06/01/1900	Date Agreed	01/07/2017	4	42832	4	Recruitment Finished
15/NI/0258	191587	A PERFORMANCE EVALUATION STUDY OF ARQUER?S MCM5 ELISA TEST TO AID IN THE DIAGNOSIS OF BLADDER CANCER	Number Agreed	09/05/1900	09/05/1900	Date Agreed	31/12/2016	295	42794	295	Recruitment Finished
16/YH/0004	190267	A Phase II, Single Arm, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of MOR00208 Combined with Idelalisib in Patients with Relapsed or Refractory CLL/SLL Previously Treated with Bruton?s Tyrosine Kinase (BTK) Inhibitor	Number Agreed	01/01/1900	01/01/1900	Date Agreed	29/01/2021	0	43046	0	Recruitment Finished
15/LO/1879	186859	A Randomized, Open-label Study of Ponatinib Versus Nilotinib in Patients with Chronic Myeloid Leukemia in Chronic Phase Following Resistance to Imatinib	Number Agreed	04/01/1900	04/01/1900	Date Agreed	15/12/2022	0	42865	0	Withdrawn By Sponsor
15/EM/0344	183906	A Randomized, Double-blind, Placebo-controlled Study of the Safety and Efficacy of Amatuximab in Combination with Pemetrexed and Cisplatin in Subjects with Unresectable Malignant Pleural Mesothelioma	Number Agreed	02/01/1900	02/01/1900	Date Agreed	31/10/2017	2	42746	2	Recruitment Finished
15/WA/0358	189344	An exploratory, open-label, multicenter study to evaluate the safety and efficacy of a two-dose regimen of ATIR101, a T-lymphocyte enriched leukocyte preparation depleted ex vivo of host alloreactive T-cells (using photodynamic treatment), in patients with	Number Agreed	02/01/1900	02/01/1900	Date Agreed	10/03/2017	3	43060	3	Recruitment Finished
16/LO/0014	190759	A Prospective Multicenter Phase III Clinical Evaluation of the Safety and Efficacy of Lumason/SonoVue in Subjects Undergoing Pharmacologic Stress Echocardiography with Dobutamine for the Diagnosis of Coronary Artery Disease	Range Agreed	10/01/1900	12/01/1900	Date Agreed	10/04/2017	12	42842	12	Recruitment Finished
13/NE/0005	100377	Product Surveillance Registry ? A prospective, non-interventional registry providing continuing evaluation and periodic reporting of product safety, effectiveness and patient outcomes across Medtronic market-released products within diabetes, cardiac rhyth	Number Agreed	07/01/1900	07/01/1900	Date Agreed	28/04/2017	8	42853	8	Recruitment Finished
15/LO/0075	164748	A Phase 3 Multicentre, Double-Blind, Randomised, Active Comparator-Controlled Clinical Trial to Evaluate the Safety and Efficacy of Doravirine (MK-1439) 100 mg Once Daily Versus Darunavir 800 mg Once Daily plus Ritonavir 100 mg Once Daily, Each in Combinat	Not Available / Not Agreed			Not Available / Not Agreed			42767	0	Recruitment Finished
15/SC/0409	183061	Safety and Efficacy of Abicipar Pegol in Patients with Neovascular Age-related Macular Degeneration	Number Agreed	10/01/1900	10/01/1900	Date Agreed	03/06/2019	0	42832	0	Recruitment Finished
15/LO/1105	181406	A Randomized, Single-Blind, Multicenter Phase 2 Study to Evaluate the Activity of 2 Dose Levels of Imetelstat in Subjects with Intermediate-2 or High-Risk Myelofibrosis (MF) Relapsed/Refractory to Janus Kinase (JAK) Inhibitor	Number Agreed	03/01/1900	03/01/1900	Date Agreed	19/09/2016	0	42835	0	Withdrawn By Sponsor
16/LO/0512	185608	Intraocular pressure and tolerability Study of Preserved Bimatoprost 0.1% (BIMMD) or Tafluprost Unit Dose Preservative Free 15microgram/ml (TUDPF) (Saflutan), in patients with Ocular hypertension or glaucoma suitable for prostaglandin therapy: A Randomize	Number Agreed	02/01/1900	02/01/1900	Date Agreed	01/03/2017	2	42795	2	Recruitment Finished
14/LO/1834	165047	A Phase I randomised, placebo-controlled, double-blind, single and multiple ascending dose study of the tolerability and pharmacokinetics of GBT440 in healthy subjects and patients with Sickle Cell Disease	Number Agreed	04/01/1900	06/01/1900	Date Agreed	01/02/2017	6	42767	6	Recruitment Finished

14/NW/1427	166630	A Phase 3, Randomized Study Investigating the Safety of CVT-301 (Levodopa Inhalation Powder) in Parkinson?s Disease Patients With Motor Response Fluctuations (OFF Phenomena) Compared to an Observational Cohort Control	Number Agreed	04/01/1900	04/01/1900	Date Agreed	13/12/2017	0	42940	0	Recruitment Finished
14/NI/0002	143644	AN OPEN LABEL, REGISTRY STUDY OF THE SAFETY OF ILUVIEN? 190 MICROGRAMS INTRAVITREAL IMPLANT IN APPLICATOR	Number Agreed	12/01/1900	12/01/1900	Date Agreed	30/12/2016	12	42928	12	Recruitment Finished